Format
Sealed research vial
Trust signal
COA-backed inventory
Safety Data Sheet
Download SDS
Full safety documentation for this compound.
Metabolic & GLP-1 · Research grade
Lab-grade supply. Stocked in Australia.
From A$64.99
Select options below
Size
Select one
Select your preferred options to continue.
Volume pricing: orders of 3+ items are 15% off — applied automatically at checkout.
Third-party tested · 99%+ purity · Dispatched from Melbourne within 1 business day · 4.6★ on Trustpilot
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
Certificate of Analysis
Verified result: Available in document
Tirzepatide
COA-backed · third-party tested
Structural class
Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid moiety linked via a γGlu-2×OEG spacer at Lys26.
Pathways studied
Tirzepatide engages both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R, each coupling through Gs to stimulate cAMP production. Its GIPR agonism shows a differentiated β-arrestin recruitment profile relative to native GIP in cellular assays — sometimes described as partial or biased agonism — which creates distinct receptor internalisation kinetics compared with full-efficacy GIPR agonists. At GLP-1R it behaves as a full agonist with potency comparable to semaglutide in cAMP accumulation assays. The C20 fatty diacid modification confers tight albumin binding, supporting comparative half-life studies against C18-modified analogs.
Typical research focus
Dual-receptor research panels using tirzepatide typically aim to dissect how simultaneous GIP and GLP-1 pathway activation changes the net cAMP response, receptor trafficking, or downstream transcriptional outputs versus each pathway individually. Its biased GIPR profile makes it an informative tool for structure-activity studies in receptor pharmacology.
For laboratory research use only. Not for human or veterinary use, and not for human consumption. Intended for in-vitro and pre-clinical research settings only.
How to read a certificate of analysis, what purity actually measures, and how research peptides are stored and independently verified.
The questions researchers ask most.
Every batch is independently tested by Janoshik Analytical. Each product links straight to the lab's own record, so you can check the exact purity figure yourself before you buy — nothing to take on trust.
Keep vials sealed, dry, and out of direct light. Lyophilised (freeze-dried) peptides are stable at -20 °C; once reconstituted, store as noted on the product label. Full handling notes sit on every product page.
Order by 2pm for same-day dispatch from our Melbourne warehouse, otherwise the next business day, with tracked delivery Australia-wide. No customs, no border delays — it's already in the country.
More in the full FAQ · Rated 4.6★ on Trustpilot
Researchers who bought Tirzepatide also stock these.
It brings together 4 labelled variants: 10mg, 20mg, 30mg, and 15mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
Tirzepatide is generally discussed as a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid moiety linked via a γGlu-2×OEG spacer at Lys26. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
Yes. This listing includes access to a product-specific COA, which should be reviewed before use so purity, identity, and documentation checks are aligned with the project record.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
